[1]Katan M B. Apoupoprotein E isoforms, serum cholesterol, and cancer[J]. Lancet, 1986, 327(8479): 507-508.
[2]Smith G D, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?[J]. Int J Epidemiol, 2003, 32(1): 1-22.
[3]Lawlor D A, Harbord R M, Sterne J A C, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology[J]. Stat Med, 2008, 27(8): 1133-1163.
[4]Burgess S. What indeed can be tested with an instrumental variable?[J]. Eur J Epidemiol, 2018, 33(8): 695-697.
[5]Burgess S, Foley C N, Zuber V. Inferring causal relationships between risk factors and outcomes from genome-wide association study data[J]. Annu Rev Genomics Hum Genet, 2018, 19: 303-327.
[6]Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet, 2014, 23(R1): R89-R98.
[7]Gkatzionis A, Burgess S, Newcombe P J. Statistical methods for cis-Mendelian randomization with two-sample summary-level data[J]. Genet Epidemiol, 2023, 47(1): 3-25.
[8]Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference[J]. Stat Methods Med Res, 2007, 16(4): 309-330.
[9]Davies N M, Holmes M V, Davey Smith G. Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians[J]. BMJ, 2018, 362: k601.
[10]Kamstrup P R, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J]. JAMA, 2009, 301(22): 2331-2339.
[11]Linsel-Nitschke P, Götz A, Erdmann J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-a Mendelian randomisation study[J]. PLoS One, 2008, 3(8): e2986.
[12]Burgess S, Thompson S G, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies[J]. Int J Epidemiol, 2011, 40(3): 755-764.
[13]Burgess S, Small D S, Thompson S G. A review of instrumental variable estimators for Mendelian randomization[J]. Stat Methods Med Res, 2017, 26(5): 2333-2355.
[14]Burgess S, Butterworth A, Thompson S G. Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol, 2013, 37(7): 658-665.
[15]Mezzetti A, Zuliani G, Romano F, et al. Associazione Medica Sabin. Vitamin E and lipid peroxide plasma levels predict the risk of cardiovascular events in a group of healthy very old people[J]. J Am Geriatr Soc, 2001,49(5):533-537.
[16]Myung S K, Ju W, Cho B, et al. Korean Meta-Analysis Study Group. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials[J]. BMJ, 2013,346:f10.
[17]Wang T, Xu L. Circulating vitamin E levels and risk of coronary artery disease and myocardial infarction: a Mendelian randomization study[J]. Nutrients, 2019, 11(9): 2153.
[18]Haycock P C, Burgess S, Wade K H, et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies[J]. Am J Clin Nutr, 2016, 103(4): 965-978.
[19]Yan T, Zhu S J, Xie C M, et al. Coronary artery disease and atrial fibrillation: abidirectional Mendelian randomization study[J]. J Cardiovasc Dev Dis, 2022, 9(3): 69.
[20]Xu L, Borges M C, Hemani G, et al. The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study[J]. Diabetologia, 2017, 60(11): 2210-2220.
[21]Smith G D, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations[J]. Int J Epidemiol, 2004, 33(1): 30-42.
[22]Davies N M, von Hinke Kessler Scholder S, Farbmacher H, et al. The many weak instruments problem and Mendelian randomization[J]. Stat Med, 2015, 34(3): 454-468.
[23]Brion M J A, Shakhbazov K, Visscher P M. Calculating statistical power in Mendelian randomization studies[J]. Int J Epidemiol, 2013, 42(5): 1497-1501.
[24]Hartwig F P, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption[J]. Int J Epidemiol, 2017, 46(6): 1985-1998.
[25]Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525.
[26]Qi G H, Chatterjee N. Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects[J]. Nat Commun, 2019, 10(1): 1941.
[27]Dai H J, Hou T Z H, Wang Q, et al. Causal relationships between the gut microbiome, blood lipids, and heart failure: a Mendelian randomization analysis[J]. Eur J Prev Cardiol, 2023, 30(12): 1274-1282.
[28]Nikpay M. Multiomics data analysis identified CpG sites that mediate the impact of smoking on cardiometabolic traits[J]. Epigenomes, 2023, 7(3): 19.
[29]Rosoff D B, Davey Smith G, Mehta N, et al. Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: a multivariable Mendelian randomization study[J]. PLoS Med, 2020, 17(12): e1003410.
[30]Burgess S, Butterworth A, Malarstig A, et al. Use of Mendelian randomisation to assess potential benefit of clinical intervention[J]. BMJ, 2012, 345: e7325.
[31]Gill D, Burgess S. The evolution of Mendelian randomization for investigating drug effects[J]. PLoS Med, 2022, 19(2): e1003898.
[32]Burgess S, Mason A M, Grant A J, et al. Using genetic association data to guide drug discovery and development: review of methods and applications[J]. Am J Hum Genet, 2023, 110(2): 195-214.
|